RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @ahmedjo70s: يالله يا ولاد خبر كويس أهو..ال Remdesivir بتاع جليد..الشركة اللي عملت أدوية ڤيروس سي..جايب نتيجة كويسة في الحالات الحادة ..…
Resultados de uma coorte de 53 pcts tratados de modo compassivo com #remdesivir são encorajadores, especialmente em pacientes graves em ventilação mecânica (redução da mortalidade) e melhora clínica geral (melhora de 68%) @minsaude @lhmandetta https://t.
@ICMRDELHI @MoHFW_INDIA @netshrink @AnantBhan @anupampom
Un estudio también reciente (aunque con varias limitaciones) para el uso compasivo de #remdesivir en 53 pacientes graves con #COVIDー19, encontró una mejoría clínica en el 68% para el parámetro de soporte de oxígeno y una mortalidad del 13%. https://t.co/u
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
يالله يا ولاد خبر كويس أهو..ال Remdesivir بتاع جليد..الشركة اللي عملت أدوية ڤيروس سي..جايب نتيجة كويسة في الحالات الحادة ..يا كريم يا رب
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @accpinfdprn: 📄 New today from @NEJM on @GileadSciences’s remdesivir for #COVID19 📲 https://t.co/LPlhryLTAW No comparator. 68% had cl…
RT @Kevin_W81: 🔥🔥🔥 The New England Journal of Medicine Published Remdesivir data 50 mins ago "...After 28 days of follow-up, 84% discharg…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
Remdesivir compassionate /severe #COVID19 Retrospective 7 of the 53 patients (13%) died after the completion of RDV treatment, including 6 of 34 patients (18%) who were receiving invasive ventilation and 1 of 19 (5%) who were receiving noninvasive oxygen s
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
Compassionate Use of Remdesivir for Patients with Severe #Covid-19 | NEJM https://t.co/kVEsWAS0tZ
🔥🔥🔥 The New England Journal of Medicine Published Remdesivir data 50 mins ago "...After 28 days of follow-up, 84% discharged from hospital according to Kaplan-Meier analysis...." Compassionate Use of Remdesivir for Patients with Severe Covid-19 https://
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @paomorejon: 📌Compassionate Use of Remdesivir for Patients with Severe #COVIDー19 Improvement in oxygen-support status was observed in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
From NEJM article on compassionate use of Gilead’s remdesivir, a breakdown of each patient’s improvement level https://t.co/wqXfn0TqC1 #COVID19 https://t.co/dWjAm6R1b4
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
📌Compassionate Use of Remdesivir for Patients with Severe #COVIDー19 Improvement in oxygen-support status was observed in 68% of patients, and overall mortality was 13% over a median follow-up of 18 days. Need RCT...!!! #covidtwitter https://t.co/w535
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
If there’s a therapeutic invented by this summer I might be able my wedding and a honeymoon
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @AndyBiotech: NEJM report on compassionate use of Remdesivir for 53 patients with severe #COVID19 https://t.co/gL0QKtw39L … 36/53 (68%)…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @NedPagliarulo: Newly published in NEJM: Data on 53 #COVID19 patients treated with $GILD remdesivir through compassionate use. 36/53 s…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/pfAocqS4Lj
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/oJpm554V98
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @accpinfdprn: 📄 New today from @NEJM on @GileadSciences’s remdesivir for #COVID19 📲 https://t.co/LPlhryLTAW No comparator. 68% had cl…
RT @accpinfdprn: 📄 New today from @NEJM on @GileadSciences’s remdesivir for #COVID19 📲 https://t.co/LPlhryLTAW No comparator. 68% had cl…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
Some remdesivir data! My quick take is that mortality seems to be lower than expected, but based on Figure 2 (improvement in oxygenation) I’m not sure that remdesivir has anything to do with this. Ultimately, we need comparative data!
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
Pretty promising early data on antiviral drug remdesivir for severe #COVID_19. No control group and pretty small sample, but only 18% of ventilated patients died (18-day median follow-up), which compares favorably with ~50% fatality rate on average. https
OH WOW! This looks to be fantastic news! No wonder Gilead was ramping up production.
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
!!!
RT @NedPagliarulo: Newly published in NEJM: Data on 53 #COVID19 patients treated with $GILD remdesivir through compassionate use. 36/53 s…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @Dr_Aust_PhD: This looks encouraging for an early trial. Remdesivir is an inhibitor of the viral (RNA-dep) RNA polymerase. If this holds…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @AndyBiotech: NEJM report on compassionate use of Remdesivir for 53 patients with severe #COVID19 https://t.co/gL0QKtw39L … 36/53 (68%)…
Wśród 53 poddanych leczeniu remdesivirem pacjentów, odnotowano poprawę kliniczną u 68%. Ocena skuteczności wymaga dalszych badań. https://t.co/8bjgwifFu1
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
This looks encouraging for an early trial. Remdesivir is an inhibitor of the viral (RNA-dep) RNA polymerase. If this holds up, I reckon what we need is an inhibitor of one other virally-encoded protein to combine it with... protease inhibitors would be the
RT @AndyBiotech: NEJM report on compassionate use of Remdesivir for 53 patients with severe #COVID19 https://t.co/gL0QKtw39L … 36/53 (68%)…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @AndyBiotech: NEJM report on compassionate use of Remdesivir for 53 patients with severe #COVID19 https://t.co/gL0QKtw39L … 36/53 (68%)…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @NedPagliarulo: Newly published in NEJM: Data on 53 #COVID19 patients treated with $GILD remdesivir through compassionate use. 36/53 s…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @gonzobreakout: $GILD remdesivir compassionate use shows 68% clinical improvement -NEJM #coronavirus #covid19 #sarscov2 https://t.co/Dwy…
En esta cohorte de pacientes hospitalizados x #COVID19 grave que fueron tratados con remdesivir, se observó mejoría clínica en 36 de 53 pacientes. La medición de la eficacia requerirá ensayos aleatorios controlados con placebo de la terapia con remdesivir.
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
$GILD remdesivir compassionate use shows 68% clinical improvement -NEJM #coronavirus #covid19 #sarscov2
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
This is very good
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @AndyBiotech: NEJM report on compassionate use of Remdesivir for 53 patients with severe #COVID19 https://t.co/gL0QKtw39L … 36/53 (68%)…
In this cohort of patients hospitalized for severe Covid19 who were treated with compassionate-use #remdesivir , clinical improvement was observed in 36 of 53 patients (68%) #Covid19 @NEJM #OncoAlert #niioncologii https://t.co/aT7x0xQvDK
Newly published in NEJM: Data on 53 #COVID19 patients treated with $GILD remdesivir through compassionate use. 36/53 saw improvement in oxygen support class 25/53 discharged Seven, however, passed away. https://t.co/3DgigeoF6x https://t.co/PBTqjvNtP4
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @AndyBiotech: NEJM report on compassionate use of Remdesivir for 53 patients with severe #COVID19 https://t.co/gL0QKtw39L … 36/53 (68%)…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
Still need a placebo-controlled trial, but just maybe promising https://t.co/RWMzNupEcy
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @AndyBiotech: NEJM report on compassionate use of Remdesivir for 53 patients with severe #COVID19 https://t.co/gL0QKtw39L … 36/53 (68%)…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
The 13% mortality observed in this remdesivir compassionate-use cohort is noteworthy, considering the severity of disease in this patient population (75% of patients were over 60 years of age, and had coexisting condition) https://t.co/3wWCNYYe9A
This is great news #helenesgreenshoots
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
Crazy that the antiviral (hopefully) works against a virus and the immunosuppressant doesn't.
RT @Transplant_Doc: Compassionate Use of #Remdesivir for Patients with Severe Covid-19. In 61 patients hospitalized for severe Covid-19 cli…
Encouraging Remdesivir data https://t.co/ty4BBucpG3